显效:经肝组织病理学检查肝纤维化分期下降≥2期;肝纤维化血清学标志物(ⅣC、HA、PⅢP及LN含量)两项以上测定值较治疗前下降≥50%或恢复正常;血清肝功能指标基本恢复正常,证候明显改善。 有效:肝纤维化血清学标志物(ⅣC、HA、LN及PⅢP含量)有任何两项测定值较治疗前下降≥25%;血清肝功能指标改善和(或)肝组织病理学检查肝纤维化分期较治疗前下降1期,证候改善。 无效:未达到有效标准者。 参
考
文
献 [1]Liaw YF, Tai DI,
Chu CM, et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology, 1988, 8: 493-496. [2]Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology, 2002, 35: 1522-1527. [3]Wu GC, Zhou WP, Zhao YR, et al. Study on the natural history of chronic hepatitis B. Zhonghua Ganzangbing Zazhi, 2002, 10: 46-48. 巫贵成,周卫平,赵有蓉,等.慢性乙型肝炎自然史的研究.中华肝脏病杂志,2002,10:
46-48. [4]Hepatic Fibrosis Study Group of Chinese Liver Diseases Association. Consensus on evaluation of the diagnosis and efficacy of hepatic fibrosis. Zhonghua Ganzangbing Zazhi, 2002, 10: 327-328. ....................(以下略) |